Literature DB >> 15294010

Incorporation of statistical uncertainty in health economic modelling studies using second-order Monte Carlo simulations.

Mark J C Nuijten1.   

Abstract

Health economic modelling studies are of interest to many parties with different responsibilities and diverging interests. Therefore, it is obvious that recognising the relevance of statistical uncertainty and dealing with it appropriately are required to obtain unbiased results from health economic modelling studies, especially when those data are being used for reimbursement decisions. In this manuscript we explore the relevance of the incorporation of statistical uncertainty in a health economic model and identify various types of statistical uncertainty. The concepts were applied to a hypothetical Markov model for a hypothetical antiparkinsonian (AP) product. The method was based on the incorporation of probability distributions in the input variables using a second-order Monte Carlo simulation and the definition of minimum relevant differences for clinical and economic input variables and outcomes. Our paper shows that the outcomes of a health economic model might be severely biased when statistical uncertainty is not taken into account, which justifies the need for the incorporation of statistical uncertainty in a health economic model.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15294010     DOI: 10.2165/00019053-200422120-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  13 in total

1.  Bridging decision analytic modelling with a cross-sectional study. Application to Parkinson's disease.

Authors:  M J Nuijten
Journal:  Pharmacoeconomics       Date:  2000-03       Impact factor: 4.981

2.  Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis.

Authors:  M J Nuijten; P van Iperen; C Palmer; B J van Hilten; E Snyder
Journal:  Value Health       Date:  2001 Jul-Aug       Impact factor: 5.725

3.  Measuring uncertainty in complex decision analysis models.

Authors:  G Parmigiani
Journal:  Stat Methods Med Res       Date:  2002-12       Impact factor: 3.021

4.  Economic analysis in randomized control trials.

Authors:  M E Adams; N T McCall; D T Gray; M J Orza; T C Chalmers
Journal:  Med Care       Date:  1992-03       Impact factor: 2.983

5.  Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America.

Authors:  K Clemens; R Townsend; F Luscombe; J Mauskopf; J Osterhaus; J Bobula
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

6.  Modelling in economic evaluation: an unavoidable fact of life.

Authors:  M J Buxton; M F Drummond; B A Van Hout; R L Prince; T A Sheldon; T Szucs; M Vray
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

7.  Measuring sensitivity in pharmacoeconomic studies. Refining point sensitivity and range sensitivity by incorporating probability distributions.

Authors:  M J Nuijten
Journal:  Pharmacoeconomics       Date:  1999-07       Impact factor: 4.981

8.  Economic evaluation and health care. What does it mean?

Authors:  R Robinson
Journal:  BMJ       Date:  1993-09-11

9.  Are guidelines for peer-reviewing economic evaluations necessary? A survey of current editorial practice.

Authors:  T Jefferson; V Demicheli
Journal:  Health Econ       Date:  1995 Sep-Oct       Impact factor: 3.046

10.  Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach.

Authors:  P Doubilet; C B Begg; M C Weinstein; P Braun; B J McNeil
Journal:  Med Decis Making       Date:  1985       Impact factor: 2.583

View more
  7 in total

Review 1.  Modelling the cost effectiveness of treatments for Parkinson's disease: a methodological review.

Authors:  Judith Dams; Bernhard Bornschein; Jens Peter Reese; Annette Conrads-Frank; Wolfgang H Oertel; Uwe Siebert; Richard Dodel
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

2.  Incorporation of uncertainty in health economic modelling studies.

Authors:  Anthony O'Hagan; Christopher McCabe; Ron Akehurst; Alan Brennan; Andrew Briggs; Karl Claxton; Elisabeth Fenwick; Dennis Fryback; Mark Sculpher; David Spiegelhalter; Andrew Willan
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Incorporation of uncertainty in health economic modelling studies.

Authors:  Mark Nuijten
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 4.  Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide.

Authors:  James E Stahl
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

5.  Cost-effectiveness of primary prevention of paediatric asthma: a decision-analytic model.

Authors:  G Feljandro P Ramos; Antoinette D I van Asselt; Sandra Kuiper; Johan L Severens; Tanja Maas; Edward Dompeling; J André Knottnerus; Onno C P van Schayck
Journal:  Eur J Health Econ       Date:  2013-10-06

6.  The implications of regional and national demographic projections for future GMS costs in Ireland through to 2026.

Authors:  Aisling Conway; Martin Kenneally; Noel Woods; Andreas Thummel; Marie Ryan
Journal:  BMC Health Serv Res       Date:  2014-10-21       Impact factor: 2.655

7.  On the Use of Markov Models in Pharmacoeconomics: Pros and Cons and Implications for Policy Makers.

Authors:  Andrea Carta; Claudio Conversano
Journal:  Front Public Health       Date:  2020-10-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.